Chronic periodontal disease and related systemic pathologies are initiated and perpetuated by specialist pathogens such as Porphyromonas gingivalis . Small exosome-like structures released in the form of outer membrane vesicles (OMVs) are a reservoir for key virulence factors of this perioodontopathogen. We have embarked on developing biologics that target OMVs in disease.

The administration of therapeutic monoclonal antibody to patients can lead to the occurrence of anti-drug antibodies, which can reduce the efficacy of treatment. As more antibody drugs are approved, this is a growing problem that is attracting attention from frontline clinicians. We developed a platform for the detection of IgG anti-drug antibodies for all therapeutic monoclonal antibodies.